EGFR and neoplasm: EGFR mutations (e.g., exon 19 deletions, L858R) are prevalent in LUAD and drive constitutive activation of EGFR tyrosine kinase, promoting tumor proliferation and metastasis via PI3K-AKT [27] and MAPK-ERK pathways [28], which regulate cell cycle progression [29,30].